Bone DiseaseCPCNCT02575352
Calcium Phosphate Cement Registry (CPC Registry)
An observational study of Bone Disease and Fracture Bone, run by Graftys SA at 11 sites in 5 countries.
Trial summary
CPC REGISTRY is a multi-center, international, prospective, open-label, observational study on the use of injectable calcium phosphate cements for the treatment of bone defects in adults. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bone Disease, Fracture Bone, Bone Cyst
- How many people
- 500 participants
- Where
- 11 sitesin 5 countries
- Study dates
- May 2015to May 2021
- How long will I take part?
- 24 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients eligible and planned for bone defect treatment who meet predefined criteria in Instructions For Use (IFU) of GRAFTYS®HBS/ GRAFTYS®Quickset.
Who may be able to join
- Bone skeletal defects that are not intrinsic to the stability of bone structure OR site which can be stabilized
- Bone defects from surgery, trauma, tumor or cyst
- Age ≥ 18 years
- Patient information and signed informed consent form (for data collection)
- Affiliation to a Social Security System schema (or similar system)
Who cannot join
- Patients undergoing radiotherapy or chemotherapy
- Patients with inflammatory bone disease
- Patients with a calcium metabolism anomaly, severe metabolic disease, vascular or neurological diseases, or immunological deficiencies
- Bone site which can lead to the product passing into the joint cavities without appropriate controls (visual, arthroscopic, lavage…).
- Bone site which can lead to the product passing into the meningeal spaces
- Vertebroplasty and kyphoplasty
Show all 13Show fewer
- Site infected or one suspected of being so
- A cranio-maxillofacial defect with a surface area larger than 25 cm2
- A site exposed to the sinus (lumen) or nasal mucosa
- Pregnant women (or likely to be) or breast-feeding women
- Inability to understand the consent and objectives of the study
- Unable to undergo medical monitoring for geographical, social or psychological reasons
- Persons who are deprived of liberty or under guardianship
Trial locations and contacts
11 sites in 5 countries.
11 sites in 5 countries
France4 sites, 4 recruiting
- Recruiting
Hôpital La Timone
Marseille, 13385
Sébastien PARRATTE, MD, Prof.
Sébastien PARRATTE, MD, Prof.
- Recruiting
Study site
Marseille
- Recruiting
Study site
Paris
- Recruiting
Study site
Saint-Louis
Germany3 sites, 3 recruiting
- Recruiting
Study site
Kiel
- Recruiting
Study site
Ratzeburg
- Recruiting
Study site
Würzburg
Italy2 sites, 2 recruiting
- Recruiting
Study site
Palermo
- Recruiting
Study site
Piacenza
About this study
Official title: Observational Prospective Multi-center International Study on the Use of Injectable Calcium Phosphate Cements for the Treatment of Bone Defects in Adults.
CPC REGISTRY is a multi-center, international, prospective, open-label, observational study on the use of injectable calcium phosphate cements for the treatment of bone defects in adults. All patients will be treated with any of the two injectable calcium phosphate bone substitutes (GRAFTYS®HBS/GRAFTYS®Quickset or their private labels) according to standard clinical practice and according to the information provided by GRAFTYS manufacturer in respective device Instructions For Use (IFU).
Read the detailed description
The objective of this observational prospective study is to collect safety and performance data relating to the use of injectable Calcium Phosphate Cements "GRAFTYS®HBS/GRAFTYS®Quickset (or their private labels)" in routine clinical practice from various international hospitals. Therefore this observational study will allow to support data about risk management (established at the end of the product development); and to enhance the current clinical evaluation of products with new clinical data (for longer follow-up). The collected data of this observational study will be "non-identifying data". The patient must have signed a Written Consent Form (for data collection) prior to any data being entered into the electronic Case Report Form.
Patients will be followed as per local standard medical practices of the center for two years. Five follow-up visits/phone calls will be collected (at 3 months (+/-14 days), 6 months (+/- 14 days), 9 months (+/-21 days), 12 months (+/- 30 days) and 24 months (+/-60 days)). Each visit/phone call includes the collection of Adverse Events, the measurement of health status (quality of life and functional scores) and the X-ray scoring (if X-ray imaging is available). No additional exams (other than the routine clinical practice) are requested. The surgeons have to follow their usual practices (e.g. X-Rays have to be performed only if they are scheduled in the routine clinical practice).
All Adverse Events will be collected and monitored at each follow-up visit or follow-up phone call. All Serious Adverse Events must be described via a Serious Adverse Event form in e-CRF and all Adverse Device Effects must be described via a "Product Complaint Form" in e-CRF.
Descriptive analyses will be performed in order to describe: nature of adverse events, their distribution and frequency. Moreover, all factors which may appear predictive for the rate of adverse events will be analyzed (age, sex, amount of CPC injected, delivery system used, diabetes history, smoking habits, alcohol consumption, concomitant treatments/diseases…). For all time-dependent events, life-tables will be able to calculate using the Kaplan Meier estimate method, for a period starting on the date of the procedure up to and including the 24-months follow-up visit.
- Conditions
- Bone Disease, Fracture Bone, Bone Cyst
- Keywords
- Bone Substitute, Calcium Phosphate Cement, GRAFTYS, GRAFTYS®HBS, GRAFTYS®QUICKSET, Bone void filler, Bone growth, Registry, Bone defect, Revision arthroplasty, Arthrodesis
- Medical subject headings
- Bone Diseases, Fractures, Bone, Bone Cysts, Ankylosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Adverse Device Effect rate
Rate of Adverse Events related to bone substitutes (registry devices) for the follow-up period of patients.
Measured: For 24 months
Secondary outcomes (26)
Technical Success rate
Technical Success rate defined as successful delivery of the bone substitute in the target defect bone without evidence of delivery device or bone substitute malfunction. (NOTE: Malfunction is definied as a failure of the medical device to perform in accordance with its intended purpose when used in accordance with the Instructions For Uses (IFU)).
Measured: At surgical procedure
Device Deficiencies rate
Device deficiency is defined as an inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance.
NOTE: Device deficiencies include malfunctions, use errors, and inadequate labelling.
Measured: At surgical procedure
Serious Adverse Events rate in the peroperative period
Serious Adverse Event is defined as any adverse event that:
- Led to a death,
- Led to serious deterioration in health of the subject that either resulted in:
- a life-threatening illness or injury, or
- a permanent impairment of a body structure or a body function, or
- in-patient or prolonged hospitalization, or
- medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
- Led to fetal distress, fetal death or a congenital abnormality or birth defect.
Measured: At surgical procedure
Serious Adverse Events rate during the follow-up period
Serious Adverse Event is defined as any adverse event that:
- Led to a death,
- Led to serious deterioration in health of the subject that either resulted in:
- a life-threatening illness or injury, or
- a permanent impairment of a body structure or a body function, or
- in-patient or prolonged hospitalization, or
- medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
- Led to fetal distress, fetal death or a congenital abnormality or birth defect.
Measured: 3 months post index procedure
Serious Adverse Events rate during the follow-up period
Serious Adverse Event is defined as any adverse event that:
- Led to a death,
- Led to serious deterioration in health of the subject that either resulted in:
- a life-threatening illness or injury, or
- a permanent impairment of a body structure or a body function, or
- in-patient or prolonged hospitalization, or
- medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
- Led to fetal distress, fetal death or a congenital abnormality or birth defect.
Measured: 6 months post index procedure
Serious Adverse Events rate during the follow-up period
Serious Adverse Event is defined as any adverse event that:
- Led to a death,
- Led to serious deterioration in health of the subject that either resulted in:
- a life-threatening illness or injury, or
- a permanent impairment of a body structure or a body function, or
- in-patient or prolonged hospitalization, or
- medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
- Led to fetal distress, fetal death or a congenital abnormality or birth defect.
Measured: 9 months post index procedure
Serious Adverse Events rate during the follow-up period
Serious Adverse Event is defined as any adverse event that:
- Led to a death,
- Led to serious deterioration in health of the subject that either resulted in:
- a life-threatening illness or injury, or
- a permanent impairment of a body structure or a body function, or
- in-patient or prolonged hospitalization, or
- medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
- Led to fetal distress, fetal death or a congenital abnormality or birth defect.
Measured: 12 months post index procedure
Serious Adverse Events rate during the follow-up period
Serious Adverse Event is defined as any adverse event that:
- Led to a death,
- Led to serious deterioration in health of the subject that either resulted in:
- a life-threatening illness or injury, or
- a permanent impairment of a body structure or a body function, or
- in-patient or prolonged hospitalization, or
- medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
- Led to fetal distress, fetal death or a congenital abnormality or birth defect.
Measured: 24 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
Measured: 3 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
Measured: 6 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
Measured: 9 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
Measured: 12 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
Measured: 24 months post index procedure
Quality of life score at baseline (EQ-5D-3L)
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
Measured: At baseline (pre-operative)
Quality of life score evolution after surgery (EQ-5D-3L)
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
Measured: 3 months post index procedure
Quality of life score evolution after surgery (EQ-5D-3L)
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
Measured: 6 months post index procedure
Quality of life score evolution after surgery (EQ-5D-3L)
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
Measured: 9 months post index procedure
Quality of life score evolution after surgery (EQ-5D-3L)
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
Measured: 12 months post index procedure
Quality of life score evolution after surgery (EQ-5D-3L)
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
Measured: 24 months post index procedure
Functional score at baseline (if applicable according to the type of bone defect/medical indication).
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
- Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
- Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
- Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
- Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.
Measured: At baseline (pre-operative)
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
- Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
- Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
- Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
- Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.
Measured: 3 months post index procedure
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
- Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
- Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
- Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
- Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.
Measured: 6 months post index procedure
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
- Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
- Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
- Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
- Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.
Measured: 9 months post index procedure
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
- Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
- Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
- Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
- Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.
Measured: 12 months post index procedure
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
- Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
- Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
- Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
- Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.
Measured: 24 months post index procedure
Surgeon's Satisfaction survey with registry device
Surgeon's Satisfaction survey with registry device (about mixing ability, injecting ability and moldability) thanks to a 100-mm Visual Analog Scale (VAS). A score of zero indicated absolutely inacceptable, while a score of 100 indicated very satisfying.
Measured: At surgical procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2015 (estimated)
- Study startMay 2015
- Primary completionMay 2021 (estimated)
- Study completionMay 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Bone DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 24 Months
Sponsor and investigators
- Lead sponsor
- Graftys SA
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Clinfile
- Responsible party
- Sponsor
- Investigators
- Sébastien PARRATTE, MD, Prof, Principal investigator, Hospital of "LA TIMONE"
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02575352
- Sponsor's protocol ID
- GR-NI-INJ
- Acronym
- CPC
- Status last verified
- May 2018
- First submitted
- 12 Oct 2015
- Last updated
- 25 May 2018
- Results posted
- No
- Data monitoring committee
- No
Publications
Hoelscher-Doht S, Ewald A, Fuchs A, Otto P, Bator J, Grunz JP, Kneist K, Bogelein L, Gbureck U. Osteointegration and remodeling of a novel mineral magnesium phosphate-based bone glue in-vivo. J Biomater Appl. 2025 Jul;40(1):82-91. doi: 10.1177/08853282251326033. Epub 2025 Mar 14.
PubMed 40083317
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Prospective Multi-center International Study on the Use of Injectable Calcium Phosphate Cements for the Treatment of Bone Defects in Adults.
- ClinicalTrials.gov ID
- NCT02575352
- Acronym / sponsor ID
- CPC / GR-NI-INJ
- Conditions
- Bone Disease, Fracture Bone, Bone Cyst
- Keywords
- Bone Substitute, Calcium Phosphate Cement, GRAFTYS, GRAFTYS®HBS, GRAFTYS®QUICKSET, Bone void filler, Bone growth, Registry
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Graftys SAIndustry (pharma, biotech, devices)
- Collaborators
- Clinfile
- Study start
- May 2015 (actual)
- Primary completion
- May 2021 (estimated)
- Study completion
- May 2021 (estimated)
- First posted
- 14 Oct 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CPC REGISTRY is a multi-center, international, prospective, open-label, observational study on the use of injectable calcium phosphate cements for the treatment of bone defects in adults. All patients will be treated with any of the two injectable calcium phosphate bone substitutes (GRAFTYS®HBS/GRAFTYS®Quickset or their private labels) according to standard clinical practice and according to the information provided by GRAFTYS manufacturer in respective device Instructions For Use (IFU).
Detailed description
The objective of this observational prospective study is to collect safety and performance data relating to the use of injectable Calcium Phosphate Cements "GRAFTYS®HBS/GRAFTYS®Quickset (or their private labels)" in routine clinical practice from various international hospitals. Therefore this observational study will allow to support data about risk management (established at the end of the product development); and to enhance the current clinical evaluation of products with new clinical data (for longer follow-up). The collected data of this observational study will be "non-identifying data". The patient must have signed a Written Consent Form (for data collection) prior to any data being entered into the electronic Case Report Form.
Patients will be followed as per local standard medical practices of the center for two years. Five follow-up visits/phone calls will be collected (at 3 months (+/-14 days), 6 months (+/- 14 days), 9 months (+/-21 days), 12 months (+/- 30 days) and 24 months (+/-60 days)). Each visit/phone call includes the collection of Adverse Events, the measurement of health status (quality of life and functional scores) and the X-ray scoring (if X-ray imaging is available). No additional exams (other than the routine clinical practice) are requested. The surgeons have to follow their usual practices (e.g. X-Rays have to be performed only if they are scheduled in the routine clinical practice).
All Adverse Events will be collected and monitored at each follow-up visit or follow-up phone call. All Serious Adverse Events must be described via a Serious Adverse Event form in e-CRF and all Adverse Device Effects must be described via a "Product Complaint Form" in e-CRF.
Descriptive analyses will be performed in order to describe: nature of adverse events, their distribution and frequency. Moreover, all factors which may appear predictive for the rate of adverse events will be analyzed (age, sex, amount of CPC injected, delivery system used, diabetes history, smoking habits, alcohol consumption, concomitant treatments/diseases…). For all time-dependent events, life-tables will be able to calculate using the Kaplan Meier estimate method, for a period starting on the date of the procedure up to and including the 24-months follow-up visit.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 24 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients eligible and planned for bone defect treatment who meet predefined criteria in Instructions For Use (IFU) of GRAFTYS®HBS/ GRAFTYS®Quickset.
Key inclusion criteria (5 listed)
- Bone skeletal defects that are not intrinsic to the stability of bone structure OR site which can be stabilized
- Bone defects from surgery, trauma, tumor or cyst
- Age ≥ 18 years
- Patient information and signed informed consent form (for data collection)
- Affiliation to a Social Security System schema (or similar system)
Key exclusion criteria (13 listed)
- Patients undergoing radiotherapy or chemotherapy
- Patients with inflammatory bone disease
- Patients with a calcium metabolism anomaly, severe metabolic disease, vascular or neurological diseases, or immunological deficiencies
- Bone site which can lead to the product passing into the joint cavities without appropriate controls (visual, arthroscopic, lavage…).
- Bone site which can lead to the product passing into the meningeal spaces
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Adverse Device Effect rate
Time frame: For 24 months
Rate of Adverse Events related to bone substitutes (registry devices) for the follow-up period of patients.
26 secondary outcomes
Technical Success rate
Time frame: At surgical procedure
Device Deficiencies rate
Time frame: At surgical procedure
Serious Adverse Events rate in the peroperative period
Time frame: At surgical procedure
Serious Adverse Events rate during the follow-up period
Time frame: 3 months post index procedure
Serious Adverse Events rate during the follow-up period
Time frame: 6 months post index procedure
Serious Adverse Events rate during the follow-up period
Time frame: 9 months post index procedure
Serious Adverse Events rate during the follow-up period
Time frame: 12 months post index procedure
Serious Adverse Events rate during the follow-up period
Time frame: 24 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
Time frame: 3 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
Time frame: 6 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
Time frame: 9 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
Time frame: 12 months post index procedure
Bone reconstruction evolution after surgery (if X-rays are available)
Time frame: 24 months post index procedure
Quality of life score at baseline (EQ-5D-3L)
Time frame: At baseline (pre-operative)
Quality of life score evolution after surgery (EQ-5D-3L)
Time frame: 3 months post index procedure
Quality of life score evolution after surgery (EQ-5D-3L)
Time frame: 6 months post index procedure
Quality of life score evolution after surgery (EQ-5D-3L)
Time frame: 9 months post index procedure
Quality of life score evolution after surgery (EQ-5D-3L)
Time frame: 12 months post index procedure
Quality of life score evolution after surgery (EQ-5D-3L)
Time frame: 24 months post index procedure
Functional score at baseline (if applicable according to the type of bone defect/medical indication).
Time frame: At baseline (pre-operative)
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time frame: 3 months post index procedure
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time frame: 6 months post index procedure
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time frame: 9 months post index procedure
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time frame: 12 months post index procedure
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time frame: 24 months post index procedure
Surgeon's Satisfaction survey with registry device
Time frame: At surgical procedure
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2018.
- Derived from this study: PubMed 40083317Hoelscher-Doht S, Ewald A, Fuchs A, Otto P, Bator J, Grunz JP, Kneist K, Bogelein L, Gbureck U. Osteointegration and remodeling of a novel mineral magnesium phosphate-based bone glue in-vivo. J Biomater Appl. 2025 Jul;40(1):82-91. doi: 10.1177/08853282251326033. Epub 2025 Mar 14.
Related trials for Bone Disease
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
Not yet recruiting
Exercise and Fall Prevention for Fracture Reduction
Osteopenia, Osteoporosis
Active, not recruiting
Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes
Type 2 Diabetes, Osteoporosis
RecruitingObservational study
A Natural History Study of Bone and Mineral Disorders
Tumor Induced Osteomalcia, Osteomalacia
RecruitingObservational study
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Adrenal Gland Neoplasm, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sébastien PARRATTE, MD, Prof principal investigator
Hospital of "LA TIMONE"
11 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bone Disease and Fracture Bone, run by Graftys SA at 11 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 May 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in France, Germany, Italy, Martinique, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mehan ALTAIFI (+33(0) 442 603 000, mehan.altaifi@graftys.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adverse Device Effect rate (time frame: For 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02575352, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2018; AzTrials last refreshed its copy on 30 Oct 2026.